STEM CELL AGENCY AGENDA

MEETING NOTICE AND AGENDA
REGULAR MEETING OF THE
INDEPENDENT CITIZENS’ OVERSIGHT COMMITTEE
TO THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE

Organized Pursuant To The
CALIFORNIA STEM CELL RESEARCH AND CURES ACT

Wednesday, February 3rd, 2010
4:00-9:00 PM

Webcast:
url: http://65.197.1.15/att/confcast
Conference ID# 141973
(Some browsers will warn of forgery using this URL. It is safe to ignore the warning and continue to the webcast.)

Locations:
Hotel Whitcomb
1231 Market Street
San Francisco, CA 94103

The Sherry Lansing Foundation
2121 Avenue of the Stars, Suite 2020
Los Angeles, CA 90067

The Salk Institute for Biological Studies
10010 North Torrey Pines Road
La Jolla, CA 92037

AND

Thursday, February 4th, 2010
9:30 AM-5:00 PM (Estimated)

URL: http://65.197.1.15/att/confcast
Conference ID# 141977
(Some browsers will warn of forgery using this URL. It is safe to ignore the warning and continue to the webcast.)

Locations:
UCSF Mission Bay Conference Center
Robertson Auditorium
1675 Owens Street
San Francisco, CA 94158

 The Sherry Lansing Foundation
2121 Avenue of the Stars, Suite 2020
Los Angeles, CA 90067

The Salk Institute for Biological Studies
10010 North Torrey Pines Road
La Jolla, CA 92037

1. Call to Order.

2. Pledge of Allegiance.

3. Roll Call.

[Members of the Public will be invited to provide testimony before or during consideration of each item. Makers of public comments are asked to limit their testimony to three (3) minutes.]

REPORTS

4. Chairman’s Report.

5. President’s Report.

 2009-2010 BUDGET REPORT

 CONSENT CALENDAR

6. Consideration of minutes from December 9-10, 2009 ICOC meeting.

ACTION ITEMS

7. Consideration of proposal to approve increase in the amount of funding for Early Translational Research Award No. TR1-01267.

8. Consideration of Concept Proposal for Tools & Technology II Awards.

9. Consideration of Revisions to CIRM MES Regulations Sections 100080 & 100090.

Supplemental information: Summary of Public Comments & Responses

10. Consideration of membership for Scientific Issues Subcommittee.

Supplemental Information: Report on CIRM’s Trial Pre?Application (PreApp) Process

Supplemental Information: Key Facts Regarding Application Review at CIRM and NIH

11. Consideration of Report from Finance Subcommittee, including but not limited to, Proposed Loan Term Guidelines and Concepts for Amendments to Loan Administration Policy.

12. Consideration of concept proposal for clinical trial funding and/or concept proposal for program funding to facilitate reaching clinical trial approvals within 12 months.

CLOSED SESSION

13. Discussion of Personnel (Government Code section 11126, subdivision (a); Health & Safety Code section 125290.30(d) (3) (D)).

Public report of any action taken, if necessary, during closed session.

DISCUSSION ITEMS

14. Public comment. The Committee will accept public testimony on any matter under its jurisdiction that is not on the agenda, but the Committee cannot act on any such matter at this meeting.

THE ORDER OF BUSINESS MAY BE CHANGED WITHOUT NOTICE.

**NOTICE**

The California Institute for Regenerative Medicine and its Independent Citizens Oversight Committee, and any subcommittees thereof, comply with the Americans with Disabilities Act (ADA) by ensuring that the meeting facilities are accessible to persons with disabilities, and providing that this notice and information given to the Members of the Committee is available to the public in appropriate alternative formats when requested. If you need further assistance, including disability-related modifications or accommodations, you may contact Melissa King at the California Institute for Regenerative Medicine at 415-396-9100 no later than the day prior to the meeting.

Questions or requests for additional information prior to the Independent Citizens Oversight Committee meeting may be referred to Melissa King at the California Institute for Regenerative Medicine at mking@cirm.ca.gov or 415-396-9100.

This meeting agenda is also available on the website for the California Institute for Regenerative Medicine at http://www.cirm.ca.gov .files/transcripts/pdf/2010/02-03-10_ICOC.pdf